SCHEDULE 13G/A: Venrock Entities Maintain Significant 9.9% Stake in enGene Holdings Inc.

A group of Venrock investment entities and affiliated individuals have disclosed a collective beneficial ownership of 9.9% of enGene Holdings Inc.'s Common Shares as of December 31, 2024, according to an amended Schedule 13G filing.

Summary

• The filing is an Amendment No. 2 to a Schedule 13G, disclosing beneficial ownership of Common Shares of enGene Holdings Inc. by a group of reporting persons.
• The reporting group includes Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh.
• As of December 31, 2024, the aggregate amount beneficially owned by the reporting group is 5,046,414 Common Shares.
• This represents 9.9% of the class of enGene Holdings Inc.'s Common Shares.
• The percentage is calculated based on 50,976,676 Common Shares outstanding as of December 16, 2024, as reported in the Issuer's Annual Report on Form 10-K filed on December 19, 2024.
• The reporting persons collectively hold shared voting power and shared dispositive power over all 5,046,414 shares.
• Specifically, VHCP III holds 1,104,175 Common Shares, VHCP Co-Investment III holds 110,434 Common Shares, and VHCP EG holds 3,831,805 Common Shares.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership, indicating continued significant institutional investment in enGene Holdings Inc. without explicit positive or negative implications for the company's operations or strategy. It's a factual update on a substantial stake.

Positives

• The continued significant beneficial ownership by a prominent healthcare-focused investment group like Venrock indicates ongoing institutional confidence in enGene Holdings Inc.

Risks

• The filing includes a certification that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11, which mitigates concerns about activist investor intentions.

Future Outlook

NA

Industry Context

Venrock Healthcare Capital Partners' significant stake suggests enGene Holdings Inc. operates within the healthcare or biotechnology sector, aligning with Venrock's investment focus. This indicates continued institutional interest in the company's specific market segment.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.
• Management: Awareness of a large, stable institutional investor group, potentially influencing strategic decisions or governance discussions.

Key Dates

Keywords

enGene Holdings Inc., Venrock, Schedule 13G, beneficial ownership, common shares, institutional investor, healthcare investment, biotechnology